Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-06-03, Stock:ABBV, The news for the past five days is as follows:
2021-05-26: NEWS1: AbbVie: The Market Can't See Beyond Humira.NEWS2: AbbVie's (ABBV) Venclyxto Gets EU Nod for First-Line AML.NEWS3: AbbVie to Present at Bernstein's 37th Annual Strategic Decisions Conference.NEWS4: AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting.NEWS5: 5 Reasons Not to Sell During a Market Crash.
2021-05-27: NEWS1: 2 Stocks to Buy With Dividends Yielding More Than 3%.NEWS2: AbbVie Stock Is Tackling Its New Buy Point — Is It A Buy Right Now?.NEWS3: 5 Stocks Warren Buffett Is Selling That You Should Be Buying.
2021-05-28: nan
2021-06-01: nan
2021-06-02: NEWS1: Senate Finance Committee launches probe into AbbVie's tax practices.NEWS2: AbbVie's Rinvoq Shows Encouraging Long Term Safety, Efficacy In Rheumatoid Arthritis, Psoriatic Arthritis Patients.NEWS3: AbbVie to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference.NEWS4: Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year.NEWS5: AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress.NEWS6: AbbVie Faces U.S. Senate Pressure Over Tax Payments.NEWS7: New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress.NEWS8: 15 Most Valuable Pharmaceutical Companies In The World.

Answer: Rise